Drug
Jaktinib clinical trials
Includes 1 study of Jaktinib dihydrochloride monohydrate.
- studies test it
- 41
- open now
- 15
- in phase 3
- 7
- first study started
- 2017
Keep track of what changes. Save the jaktinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
41 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 6 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 25
- Phase 3
- 7
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 34 · Other 7
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (34) · Nanfang Hospital, Southern Medical University (2) · Ruijin Hospital (2) · Institute of Hematology & Blood Diseases Hospital, China (1) · Yujun DONG (1) · First Affiliated Hospital of Zhejiang University (1)
Often tested with
Tested in the same studies.
Nilvanstomig (4) · Itraconazole (1) · Rifampin (1) · Azacitidine (1)
Studies
Open first, then newest update. How each study uses jaktinib is read from its arms, and is right about nine times in ten.
Testing it · 41
- Jaktinib for Steroid-Refractory Acute Graft-Versus-Host DiseaseNot yet recruitingPhase 1/2Nanfang Hospital, Southern Medical UniversityNCT07885228Written as Jaktinib
- An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingPhase 1/2Ruijin HospitalNCT07883382Written as gecacitinib Hydrochloride Tablets
- Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).Not yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07476872Written as Gecacitinib
- Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With MyelofibrosisNot yet recruitingNot applicableNanfang Hospital, Southern Medical UniversityNCT07440654Written as Gecacitinib
- Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06903377Written as Gecacitinib Hydrochloride Tablets
- Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06883526Written as Gecacitinib Hydrochloride Tablets
- Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07080216Written as Gecacitinib
- Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line TherapyNot yet recruitingPhase 2Ruijin HospitalNCT07197112Written as Gecacitinib
- Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsNot yet recruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07142837Written as Gecacitinib
- Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior TherapyRecruitingPhase 1/2Yujun DONGNCT07012304Written as Gecacitinib Hydrochloride Tablets
- A Safety and Tolerability Study of JaktinibRecruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05279001Written as Jaktinib Hydrochloride Tablet
- A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.Not yet recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04971551Written as Jaktinib Hydrochloride Tablets
- A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisRecruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05676242Written as Jaktinib Hydrochloride Tablet
- An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05686629Written as Jaktinib hydrochloride tablets
- A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus PneumoniaNot yet recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05688839Written as Jaktinib hydrochloride tablets
- Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)CompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05861128Written as Jaktinib
- Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)CompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05861102Written as Jaktinib
- A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.Active, not recruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07565597Written as Gecacitinib Hydrochloride Tablets
- A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisActive, not recruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05526222Written as Jaktinib Hydrochloride Tablet
- Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia AreataCompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05255237Written as Jaktinib
See all 41 studies that test jaktinib →